Home > Updates > Research and Industry News > Luxturna, the first treatment option for hereditary retinal dystrophy with mutations of the RPE65 gene, recommended for approval by the European Medicines Agency

Luxturna, the first treatment option for hereditary retinal dystrophy with mutations of the RPE65 gene, recommended for approval by the European Medicines Agency

Newsletter Signup

To keep up to date with our news and activities,
please leave your details below

GDPR Compliance Please indicate your consent for Retina International to contact you via the email address listed for the purposes of general alerts and newsletters.